Consistent HbA1c and body weight reduction with semaglutide independent of diabetes duration: SUSTAIN 1-5 and 7 patient-level meta-analysis

被引：0
|
作者：
Madsbad, S. [1 ]
Bain, S. C. [2 ]
Chaykin, L. [3 ]
Luedemann, J. [4 ]
Furberg, J. Kjaerulff [5 ]
Larsen, J. Rask [5 ]
Yildirim, E. [5 ]
Rosenstock, J. [6 ]
机构：
[1] Univ Copenhagen, Hvidovre Hosp, Copenhagen, Denmark
[2] Swansea Univ, Sch Med, Swansea, W Glam, Wales
[3] Meridien Res, Bradenton, FL USA
[4] Diabet Ctr & Ctr Clin Studies, Diabet Falkensee, Falkensee, Germany
[5] Novo Nordisk AS, Soborg, Denmark
[6] Dallas Diabet Res Ctr Med City, Dallas, TX USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
740
引用
收藏
页码：S360 / S361
页数：2
相关论文
共 50 条
  • [1] Consistent HbA1c and Body Weight Reduction with Semaglutide Independent of Diabetes Duration-SUSTAIN 1-5 and 7 Patient-Level Meta-analysis
    Rosenstock, Julio
    Chaykin, Louis B.
    Luedemann, Joerg
    Madsbad, Sten, Sr.
    Larsen, Julie F.
    Yildirim, Emre
    Bain, Stephen C.
    DIABETES, 2018, 67
  • [2] Clinical Response (HbA1c ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA1c and Body Weight in the SUSTAIN Program
    Aroda, Vanita R.
    Larsen, Julie F.
    Ostoft, Signe Harring
    Rea, Rosangela R.
    Sugimoto, Danny
    Ziegler, Uwe
    Vilsboll, Tina
    DIABETES, 2019, 68
  • [3] Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1-5 clinical trials
    Bain, S.
    Araki, E.
    Desouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E.
    Karsbol, J. Derving
    DeVries, J.
    DIABETOLOGIA, 2017, 60 : S375 - S375
  • [4] Semaglutide Reduces HbA1c across Baseline HbA1c Subgroups across SUSTAIN 1-5 Clinical Trials
    Bain, Stephen
    Araki, Eiichi
    Desouza, Cyrus
    Garg, Satish
    Rose, Ludger
    Tsoukas, George
    Bergan, Eirik Q.
    Karsbol, Julie Derving
    Devries, J. Hans
    DIABETES, 2017, 66 : A298 - A299
  • [5] Semaglutide reduces HbA1c across baseline HbA1c subgroups across SUSTAIN 1-5 clinical trials
    Bain, S. C.
    Araki, E.
    DeSouza, C.
    Garg, S.
    Rose, L.
    Tsoukas, G.
    Bergan, E. Q.
    Karsbol, J. D.
    DeVries, J. H.
    DIABETIC MEDICINE, 2018, 35 : 81 - 81
  • [6] More Subjects Achieved Composite Reductions of=1% HbA1c,=5% Body Weight, and=5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7)
    Dungan, Kathleen M.
    Aroda, Vanita
    Knop, Filip K.
    Leiter, Lawrence A.
    Lausvig, Nanna L.
    Lindberg, Soren
    Meier, Juris J.
    DIABETES, 2018, 67
  • [7] More subjects achieved composite reductions of ≥1% HbA1c, ≥5% body weight and ≥5 mmHg SBP with semaglutide vs comparators across the SUSTAIN 1-5 and 7 trials
    Dungan, K. M.
    Aroda, V. R.
    Knop, F. K.
    Leiter, L. A.
    Lausvig, N. L.
    Lindbergh, S.
    Schwensen, J. Ferlov
    Meier, J. J.
    DIABETOLOGIA, 2018, 61 : S359 - S360
  • [8] The effect of liraglutide on HbA1c and body weight is largely independent of baseline diabetes duration
    Seufert, J. R.
    Bailey, T.
    Svendsen, C.
    Donsmark, M.
    Nauck, M. A.
    DIABETOLOGIA, 2013, 56 : S356 - S357
  • [9] Responder Analysis of Subjects Achieving HbA1c ≥1% and Weight Loss ≥5% across SUSTAIN 1-5 Clinical Trials
    Rodbard, Helena W.
    Bellary, Srikanth
    Hramiak, Irene
    Seino, Yutaka
    Silver, Robert J.
    Bergan, Eirik Q.
    Birch, Sune
    Aroda, Vanita R.
    DIABETES, 2017, 66 : A299 - A299
  • [10] Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials
    Bellary, S.
    Rodbard, H.
    Hramiak, I.
    Seino, Y.
    Silver, R.
    Bergan, E. Q.
    Birch, S.
    Aroda, V.
    DIABETIC MEDICINE, 2018, 35 : 34 - 34
12345